The glucagonostatic and insulinotropic effects of glucagon-like peptide 1 contribute equally to its glucose-lowering action.
about
Incretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitorsPancreatic α-Cell Dysfunction in Type 2 Diabetes: Old Kids on the BlockGLP-1-based strategies: a physiological analysis of differential mode of actionPhysiology of proglucagon peptides: role of glucagon and GLP-1 in health and diseaseDPP-4 inhibition and islet functionGlucagon orchestrates stress-induced hyperglycaemiaGLP-1 increases microvascular recruitment but not glucose uptake in human and rat skeletal muscle.The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss.Glucotoxicity induces abnormal glucagon secretion through impaired insulin signaling in InR1G cellsGIP and GLP-1, the two incretin hormones: Similarities and differencesEfficacy and safety of sitagliptin in Japanese patients with type 2 diabetes switched from glinidesGLP-1 receptor agonists vs. DPP-4 inhibitors for type 2 diabetes: is one approach more successful or preferable than the other?Physiology of incretins in health and disease.Stabilization of postprandial blood glucose fluctuations by addition of glucagon like polypeptide-analog administration to intensive insulin therapy.Pleiotropic effects of incretinsComparison of sitagliptin with nateglinide on postprandial glucose and related hormones in drug-naïve Japanese patients with type 2 diabetes mellitus: A pilot study.Time course of cardiometabolic alterations in a high fat high sucrose diet mice model and improvement after GLP-1 analog treatment using multimodal cardiovascular magnetic resonance.SSTR2 is the functionally dominant somatostatin receptor in human pancreatic β- and α-cells.Comparison of the Effects of Continuous Subcutaneous Insulin Infusion and Add-On Therapy with Sitagliptin in Patients with Newly Diagnosed Type 2 Diabetes MellitusImpact of insulin resistance, body mass index, disease duration, and duration of metformin use on the efficacy of vildagliptin.Linagliptin increases incretin levels, lowers glucagon, and improves glycemic control in type 2 diabetes mellitus.Pharmacological reduction of NEFA restores the efficacy of incretin-based therapies through GLP-1 receptor signalling in the beta cell in mouse models of diabetes.Medium-Term Effect of Add-On Therapy with the DPP-4 Inhibitor, Sitagliptin, in Insulin-Treated Japanese Patients with Type 2 Diabetes Mellitus.Effects of intraportal exenatide on hepatic glucose metabolism in the conscious dog.Pharmacodynamic characteristics of lixisenatide once daily versus liraglutide once daily in patients with type 2 diabetes insufficiently controlled on metformin.Comparative effects of prolonged and intermittent stimulation of the glucagon-like peptide 1 receptor on gastric emptying and glycemia.Add-on therapies to metformin for type 2 diabetes.Glucagon antagonism as a potential therapeutic target in type 2 diabetes.Molecular physiology of glucagon-like peptide-1 insulin secretagogue action in pancreatic β cells.Regulation of glucagon secretion by incretins.The role of dysregulated glucagon secretion in type 2 diabetes.The future of incretin-based therapy: novel avenues--novel targets.Choosing a gliptin.GLP-1 based therapies: differential effects on fasting and postprandial glucose.The alpha-cell as target for type 2 diabetes therapy.Comparative clinical pharmacokinetics of dipeptidyl peptidase-4 inhibitors.Secretion of glucagon-like peptide-1 in patients with type 2 diabetes mellitus: systematic review and meta-analyses of clinical studies.Physiology of incretins and loss of incretin effect in type 2 diabetes and obesity.Lixisenatide, a novel GLP-1 receptor agonist: efficacy, safety and clinical implications for type 2 diabetes mellitus.ATP-regulated potassium channels and voltage-gated calcium channels in pancreatic alpha and beta cells: similar functions but reciprocal effects on secretion.
P2860
Q26778608-FE9AEAE3-4981-4504-BC54-DBEF29B2B622Q26825393-2660DF56-D4F7-4241-8E80-E1135294547DQ26997149-2D600BB1-10B5-481A-986A-331F45EC9D36Q27027920-DCB891A9-363B-4D0C-B436-E7631C890FB4Q27028127-56067D72-F1F9-488A-9785-116DAF7EA0CAQ28068879-F4B44119-0659-405F-A1A6-DA2C2DA53627Q30418716-AB6CA574-8FB1-41DD-AFAD-E5D7EBA32932Q30596646-F587E935-79AC-48D9-A374-60DEC0B5730CQ33585517-95643510-65E9-4D9F-8280-F1A90A0EC752Q33609502-5101746D-3E01-4ED8-941D-35A5F169EB52Q33622260-815E1095-5F7D-4A66-AAC6-2F29D28C1A9AQ34547492-49568711-D3CD-4BA8-BAFF-2B09EB166DB1Q35760279-9BA86394-4A0E-4A54-9580-63AA104F401DQ35879321-3E0A6E04-BB3D-4B23-A689-4BFAB77D380DQ35968092-2D47BAE2-F8D9-4F22-A320-7EBD31F64E1BQ36082252-05E46ADC-114F-4CE9-B666-C66F73213A57Q36259181-47624A38-BBAF-4AE2-8D0E-0658146D0A22Q36382533-BE87E6E3-DF64-4BE6-B3B9-4C76DA2598BCQ36424020-AD21414C-D9FA-4FFD-9146-518A3E1EE747Q36428052-3A3EDB12-5AFE-4E19-A89E-DFF43DD53ABBQ36428096-2A89527A-7A29-41C0-8F8C-2750FB7007A5Q36508312-AC5212A3-8287-4F1B-BD52-E994AB02A7EAQ36989707-1A087EDA-3804-4373-A1F2-754607C442E8Q37051107-4D8187E0-A023-481C-AC2E-B69A608DA7BCQ37119965-0E7097E6-372A-4D95-AD53-A195DDDF5EDEQ37510200-794D37AD-E736-4189-BBC0-3188988D0D77Q37818234-A027476C-DCD8-4C0D-B121-14C0DAB1C167Q37880234-FAED4600-6A6F-4DA5-BF4E-8CBACE5277DEQ37904176-090DD6AF-CE1E-46DD-B9C1-A4A0721EF798Q37913515-E4252358-858C-4070-BB85-D8683021FD40Q37913523-F589736F-E084-4E8E-BE15-803C17E77605Q37913528-BA5F7740-F632-49A7-B942-60706A62E4F0Q37949599-8CBC53A3-F2F3-491A-A058-DE43B57F0F16Q37974712-33BBA3BC-17C8-444E-A747-F45ADFC9C8A5Q37977335-340AA63B-E99E-4190-9EA9-2B836B4C11CCQ38017726-E14B29E2-E512-496B-A5AF-EA5BEBFCB66EQ38078816-D131430E-DCB9-4ADC-9860-F8B7CB547AD3Q38122004-CAD5C90B-7643-45CF-89ED-6E809E1455C7Q38174283-BEA69882-B089-4F7B-BF59-263BE6912139Q38218351-095F1E17-70C2-4E95-B4A5-5F432A1634B7
P2860
The glucagonostatic and insulinotropic effects of glucagon-like peptide 1 contribute equally to its glucose-lowering action.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh
2010年學術文章
@zh-hant
name
The glucagonostatic and insuli ...... o its glucose-lowering action.
@en
type
label
The glucagonostatic and insuli ...... o its glucose-lowering action.
@en
prefLabel
The glucagonostatic and insuli ...... o its glucose-lowering action.
@en
P2093
P2860
P50
P356
P1433
P1476
The glucagonostatic and insuli ...... o its glucose-lowering action.
@en
P2093
Filip K Knop
Kristine J Hare
Meena Asmar
P2860
P304
P356
10.2337/DB09-1414
P407
P577
2010-02-11T00:00:00Z